



April 2, 2018

Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced the appointments of Dustin Sjuts as Vice President of Strategy and Sales, Aesthetic and Therapeutic; Ben Putman as Vice President of Digital; and Marc Korenberg as Senior Director of Commercial Operations. In addition, Erica Bazerkanian has been promoted to Vice President of Marketing, Aesthetics and Therapeutics. All four positions are newly established and will report to Todd Zavodnick, Chief Commercial Officer and President, Aesthetics & Therapeutics, who leads the company's commercial operations and launch preparations for DaxibotulinumtoxinA for Injection (RT002) in the treatment of glabellar (frown) lines.

In his new role at Revance, Mr. Sjuts will head all product sales activities, championing strategies to enhance physician relations and drive new product adoption. Most recently, he held leadership positions at Nestle Skin Health, including Business Unit Head in China and Senior Director of Marketing in the U.S. In China, he was responsible for the medical aesthetics commercial organization, leading the development and execution of the medical solutions strategy. Prior to this, Mr. Sjuts was Senior Vice President of Franchise Operations for Alphaeon. Previously, he served as Director of Sales in Eye Care and as Senior Regional Manager of Aesthetics at Allergan.

Mr. Putman will lead digital marketing and strategy activities in his new role at Revance, focused on delivering optimal customer outreach and experiences. Prior to joining the Company, he served as Senior Vice President, General Manager and Senior Vice President of Creative Technology and Innovation at JUICE Pharma Advertising. Throughout his advertising career, he has led digital marketing strategy efforts for multiple pharmaceutical and healthcare clients and has worked on over a dozen new product launches. Previously, Mr. Putman was Director of Technology at FCB Health and Director of Web Development at Harrison & Star.

In his new role, Mr. Korenberg will manage commercial operations activities at Revance, including customer excellence and relationship management, commercial analytics, commercial programs, and commercial financial management. Most recently, he was Director of Commercial, International at Allergan, after the acquisition of Zeltiq Aesthetics, Inc., where Marc served as the Director of International Finance and Operations. Prior to this, he was General Manager at Powersports East. Mr. Korenberg began his career in corporate finance and investment banking at UBS Investment Bank.

Ms. Bazerkanian's new role includes responsibility for strategic marketing, launch planning, product development and public relations. Prior to her promotion, she served as Head, Strategic Marketing at Revance, overseeing both aesthetic and therapeutic marketing and public relations initiatives. Previously, she was Senior Director of Marketing at Kythera Biopharmaceuticals, heading early market strategy and product planning for a first-of-its-kind aesthetic injectable. Prior to this, she worked on multiple product launches at Amgen in roles with increasing responsibility across sales, business analysis and marketing promotions.

"Revance continues to attract accomplished talent in the industry, and we are pleased to announce the addition of these seasoned leaders to our commercial team," said Zavodnick. "Each of these individuals possesses a proven track record and will play an important role as we implement the Revance Product Launch Velocity Plan for the successful commercialization of Revance's lead product candidate RT002 and expand our presence in both aesthetics and therapeutic medicine."

About Revance Therapeutics, Inc.

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20180402005685/en/): <https://www.businesswire.com/news/home/20180402005685/en/>

INVESTORS

Revance Therapeutics, Inc.:
Jeanie Herbert, (714) 325-3584
jherbert@revance.com

or

Burns McClellan, Inc.:
Ami Bavishi, (212) 213-0006
abavishi@burnsmc.com

or

MEDIA

General Media:

TOGORUN:

Mariann Caprino, (917) 242-1087
m.caprino@togorun.com

or

Trade Media:

Nadine Tosk, (504) 453-8344
nadinepr@gmail.com

Source: Revance Therapeutics, Inc.

News Provided by Acquire Media